Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial

Composite outcome (time-to-first event’ occurrence during the 6 months of follow-up): Symptomatic hypotension; Hyperkalaemia; Hypokalemia; eGFR drop ≥50% from baseline; or eGFR <15 ml/min/1.73m2 or renal transplant or dialysis; Increase in diuretic dose due to worsening HF; Use of intravenous diuretics for worsening HF; HF hospitalization; Death from CV causes